Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe 08:50:00 10/06/2024 pm IST 5-day change 1st Jan Change
240 CHF -1.09% Intraday chart for Roche Holding AG +3.27% -1.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: ABB, Roche, Microsoft, Apple, Tesla... Our Logo
Roche's Lung Cancer Drug Notches EU Win After 'Unprecedented' Late-stage Study Results MT
Roche: FDA clearance for virus test CF
Roche: EU approval for lung cancer CF
Roche Secures EU Approval for Early-Stage Lung Cancer Treatment MT
Roche Obtains US FDA Emergency Use Permit for Four-in-one Molecular Test MT
Roche: efficacy of Evrysdi in spinal muscular atrophy CF
Roche's Five-year Data Confirms Efficacy, Safety of Evrysdi Drug for Spinal Muscular Atrophy in Children MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug MT
AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Buy Recommendation MT
Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe DJ
The odds of rates getting cut in 2024 may be better than you think Our Logo
ROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating ZD
ROCHE HOLDINGS AG : Goldman Sachs reaffirms its Sell rating ZD
Astra's Enhertu breast cancer trial shows 'unprecedented' results RE
Astra's Enhertu delays breast cancer in patients with low HER2 levels RE
ROCHE HOLDINGS AG : Gets a Neutral rating from UBS ZD
Transcript : Roche Holding AG - Shareholder/Analyst Call
ROCHE HOLDINGS AG : Goldman Sachs remains a Sell rating ZD
Swiss Stocks Fall as Rate Jitters Intensify Amid Latest Inflation Data MT
Global markets live: BHP, Anglo American, Lenovo, Nvidia, Apple... Our Logo
European Midday Briefing : Mood Sours as Fed Rate-Cut Bets Curtailed DJ
Roche: FDA grants priority review in breast cancer CF
Roche's Metastatic Breast Cancer Treatment Granted Priority Review by US FDA MT
Roche Breast-Cancer Drug Gets Priority Review in the U.S. DJ
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
242.6 CHF
Average target price
277.5 CHF
Spread / Average Target
+14.40%
Consensus
1st Jan change Capi.
-1.96% 22TCr
+47.17% 77TCr
-6.74% 35TCr
+19.13% 33TCr
+8.45% 30TCr
+18.67% 25TCr
+10.96% 22TCr
+5.10% 16TCr
-2.64% 16TCr
+0.51% 12TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche Bolsters Pipeline With $7.3 Billion Deal For Pfizer, Roivant's Bowel Disease Drug Company